• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges

tetano

Editor, Senior Moderator
Hum Vaccin Immunother


. 2020 Sep 16;1-18.
doi: 10.1080/21645515.2020.1812313. Online ahead of print.
Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges


Idris Nasir Abdullahi[SUP] 1 [/SUP], Anthony Uchenna Emeribe[SUP] 2 [/SUP], Hafeez Aderinsayo Adekola[SUP] 3 [/SUP], Sharafudeen Dahiru Abubakar[SUP] 1 [/SUP], Amos Dangana[SUP] 4 [/SUP], Halima Ali Shuwa[SUP] 5 [/SUP], Sunday Theophilus Nwoba[SUP] 6 [/SUP], Jelili Olaide Mustapha[SUP] 7 [/SUP], Muyideen Titilope Haruna[SUP] 8 [/SUP], Kafayat Adepeju Olowookere[SUP] 9 [/SUP], Olawale Sunday Animasaun[SUP] 10 [/SUP], Charles Egede Ugwu[SUP] 11 [/SUP], Solomon Oloche Onoja[SUP] 12 [/SUP], Abdullahi Sani Gadama[SUP] 13 [/SUP], Musa Mohammed[SUP] 14 [/SUP], Isa Muhammad Daneji[SUP] 13 [/SUP], Dele Ohinoyi Amadu[SUP] 15 [/SUP], Peter Elisha Ghamba[SUP] 16 [/SUP], Nkechi Blessing Onukegbe[SUP] 17 [/SUP], Muhammad Sagir Shehu[SUP] 18 [/SUP], Chiladi Isomah[SUP] 19 [/SUP], Adamu Babayo[SUP] 13 [/SUP], Abdurrahman El-Fulaty Ahmad[SUP] 1 [/SUP]



Affiliations

Abstract

The incidence and case-fatality rates (CFRs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the etiological agent for Coronavirus Disease 2019 (COVID-19), have been rising unabated. Even though the entire world has been implementing infection prevention and control measures, the pandemic continues to spread. It has been widely accepted that preventive vaccination strategies are the public health measures for countering this pandemic. This study critically reviews the latest scientific advancement in genomics, replication pattern, pathogenesis, and immunopathology of SARS-CoV-2 infection and how these concepts could be used in the development of vaccines. We also offer a detailed discussion on the anticipated potency, efficacy, safety, and pharmaco-economic issues that are and will be associated with candidate COVID-19 vaccines.

Keywords: COVID-19; Host-virus interaction; SARS-CoV-2; Vaccine discovery.
 
Back
Top Bottom